KR102267341B1 - 관절 손상의 치료를 위한 펩티드 및 조성물 - Google Patents

관절 손상의 치료를 위한 펩티드 및 조성물 Download PDF

Info

Publication number
KR102267341B1
KR102267341B1 KR1020157027474A KR20157027474A KR102267341B1 KR 102267341 B1 KR102267341 B1 KR 102267341B1 KR 1020157027474 A KR1020157027474 A KR 1020157027474A KR 20157027474 A KR20157027474 A KR 20157027474A KR 102267341 B1 KR102267341 B1 KR 102267341B1
Authority
KR
South Korea
Prior art keywords
asn
leu
ser
gly
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157027474A
Other languages
English (en)
Korean (ko)
Other versions
KR20150125712A (ko
Inventor
크리스텐 존슨
지안 시
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20150125712A publication Critical patent/KR20150125712A/ko
Application granted granted Critical
Publication of KR102267341B1 publication Critical patent/KR102267341B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/17—Angiopoietin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1392—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from mesenchymal stem cells from other natural sources

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
KR1020157027474A 2013-03-08 2014-03-07 관절 손상의 치료를 위한 펩티드 및 조성물 Active KR102267341B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361775400P 2013-03-08 2013-03-08
US61/775,400 2013-03-08
US201461938123P 2014-02-10 2014-02-10
US61/938,123 2014-02-10
PCT/US2014/022102 WO2014138687A1 (en) 2013-03-08 2014-03-07 Peptides and compositions for treatment of joint damage

Publications (2)

Publication Number Publication Date
KR20150125712A KR20150125712A (ko) 2015-11-09
KR102267341B1 true KR102267341B1 (ko) 2021-06-21

Family

ID=50390286

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157027474A Active KR102267341B1 (ko) 2013-03-08 2014-03-07 관절 손상의 치료를 위한 펩티드 및 조성물

Country Status (38)

Country Link
US (4) US9649359B2 (enExample)
EP (2) EP2964250B1 (enExample)
JP (3) JP6567429B2 (enExample)
KR (1) KR102267341B1 (enExample)
CN (2) CN105025917B (enExample)
AP (1) AP2015008675A0 (enExample)
AU (3) AU2014225348B2 (enExample)
BR (2) BR112015021269B1 (enExample)
CA (1) CA2903448C (enExample)
CL (1) CL2015002443A1 (enExample)
CO (1) CO7461145A2 (enExample)
CR (2) CR20200290A (enExample)
CU (1) CU24301B1 (enExample)
CY (1) CY1120729T1 (enExample)
DK (1) DK2964250T3 (enExample)
EA (1) EA035158B1 (enExample)
EC (1) ECSP15042898A (enExample)
ES (1) ES2684349T3 (enExample)
HR (1) HRP20181269T1 (enExample)
HU (1) HUE038499T2 (enExample)
IL (1) IL240727B (enExample)
JO (1) JO3564B1 (enExample)
LT (1) LT2964250T (enExample)
MX (1) MX365157B (enExample)
MY (1) MY173172A (enExample)
NZ (1) NZ711037A (enExample)
PE (1) PE20151528A1 (enExample)
PH (1) PH12015501983B1 (enExample)
PL (1) PL2964250T3 (enExample)
PT (1) PT2964250T (enExample)
RS (1) RS57446B1 (enExample)
SG (1) SG11201506490TA (enExample)
SI (1) SI2964250T1 (enExample)
TN (1) TN2015000385A1 (enExample)
TW (1) TWI634124B (enExample)
UY (1) UY35368A (enExample)
WO (1) WO2014138687A1 (enExample)
ZA (1) ZA201505966B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024122720A1 (ko) * 2022-12-09 2024-06-13 (주)케어젠 연골 재생용 펩타이드 및 이의 용도

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012000914B8 (pt) 2009-07-14 2021-05-25 Irm Llc uso de polipeptídeo com atividade condrogênica, método in vitro de indução da diferenciação de células-tronco mesenquimais em condrócitos, e composição farmacêutica para aplicação intra-articular
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
KR102117501B1 (ko) 2016-10-24 2020-06-01 스미또모 가가꾸 가부시키가이샤 세퍼레이터 및 세퍼레이터를 포함하는 이차 전지
KR102049978B1 (ko) * 2016-11-09 2019-11-28 아이씨엠 주식회사 Nkx3.2 단편을 유효성분으로 포함하는 관절염의 예방 또는 치료용 약학 조성물
KR20190084287A (ko) * 2016-11-14 2019-07-16 노파르티스 아게 연골 손상 및 관절염 치료 방법 및 조성물
CN108530619B (zh) * 2017-03-01 2020-12-08 北京大学第三医院 功能化氨基酸、制备方法及由其制得的功能化氨基酸水凝胶
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
JP7555327B2 (ja) 2018-07-25 2024-09-24 ノバルティス アーゲー Ｎｌｒｐ３インフラマソーム阻害剤
AR116566A1 (es) * 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
WO2021001804A1 (en) * 2019-07-04 2021-01-07 Cadila Healthcare Limited Angptl3 based vaccine for the treatment of liver disease
KR102577697B1 (ko) * 2019-11-13 2023-09-14 주식회사 나이벡 염증 및 상처 치료용 펩타이드
JP7298496B2 (ja) 2020-01-31 2023-06-27 トヨタ自動車株式会社 車両
EP4346876A1 (en) 2021-05-24 2024-04-10 Novartis AG Methods for the treatment of osteoarthritis
TW202306970A (zh) 2021-05-24 2023-02-16 瑞士商諾華公司 用於治療骨關節炎之方法
CN113683678B (zh) * 2021-09-15 2023-11-24 山西锦波生物医药股份有限公司 一种重组i型人源化胶原蛋白c1l2t及其制备方法和用途
CN113683681B (zh) * 2021-09-15 2023-10-03 山西锦波生物医药股份有限公司 一种重组i型人源化胶原蛋白c1l3t及其制备方法和用途
WO2023084388A1 (en) 2021-11-10 2023-05-19 Novartis Ag Methods for determining the biological activity of angptl polypeptides
CN114377202B (zh) * 2021-12-16 2023-01-24 方向前 适用于软骨再生的功能化自组装miRNA/多肽复合水凝胶及其制备方法
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
WO2025169047A1 (en) 2024-02-05 2025-08-14 Novartis Ag Improved production of angptl3 mimetics

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215451A1 (en) 2001-11-16 2003-11-20 Napoleone Ferrara Composition comprising and method of using angiopoietin-like protein 3 Angptl3
WO2011008773A2 (en) 2009-07-14 2011-01-20 The Scripps Research Institute Mesenchymal stem cell differentiation

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
US5462990A (en) 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5288931A (en) 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
AU3661199A (en) 1998-04-27 1999-11-16 Zymogenetics Inc. Novel polypeptide growth factors and materials and methods for making them
JP2002533058A (ja) 1998-05-12 2002-10-08 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ９７個のヒト分泌タンパク質
AU4643699A (en) 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
KR100553300B1 (ko) 1999-03-08 2006-02-20 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
CA2365625A1 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of substances to cells
GB9912350D0 (en) 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
ES2291198T3 (es) 1999-07-20 2008-03-01 Genentech, Inc. Composiciones y procedimientos para el tratamiento de enfermedades de tipo inmunologico.
US20030013649A1 (en) 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20040249141A1 (en) 2000-10-16 2004-12-09 Audrey Goddard Tie ligand homologues
ES2381935T3 (es) 2000-10-16 2012-06-01 Genentech, Inc. Polipéptidos WISP y sus aplicaciones terapéuticas
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
US20030027751A1 (en) 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
JP2005502322A (ja) 2001-04-19 2005-01-27 ザ スクリップス リサーチ インスティテュート 非天然アミノ酸のインビボ組込み
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
FI117667B (fi) 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
EA200500475A1 (ru) 2002-09-09 2005-10-27 Нектар Терапеутикс Ал, Корпорейшн Водорастворимые полимерные алканалы
JP4444113B2 (ja) 2002-10-16 2010-03-31 ザ スクリップス リサーチ インスティテュート ケトアミノ酸の部位特異的蛋白質組込み方法
EP1558747B1 (en) 2002-10-16 2009-10-14 The Scripps Research Institute Glycoprotein synthesis
CN103215227B (zh) 2003-04-17 2015-09-16 斯克利普斯研究院 扩展真核生物遗传密码
ES2301099T3 (es) 2003-07-07 2008-06-16 The Scripps Research Institute Composiciones de parejas ortogonales lisil-arnt y aminoacil-arnt sintetasa y usos de las mismas.
WO2005007624A2 (en) 2003-07-07 2005-01-27 The Scripps Research Institute Compositions of orthogonal glutamyl-trna and aminoacyl trna synthetase pairs and uses thereof
EP1704242A4 (en) 2003-07-07 2008-06-18 Scripps Research Inst COMPOSITIONS WITH PAIRS OF ORTHOGONAL LEUCYL-TRNA AND AMINOACYL-TRNA-SYNTHETASE AND USES THEREOF
CN101151366B (zh) 2004-09-21 2012-12-19 斯克利普斯研究院 将炔基氨基酸体内掺入真细菌的蛋白
US8216804B2 (en) 2004-10-27 2012-07-10 The Scripps Research Institute Orthogonal translation components for the in vivo incorporation of unnatural amino acids
US20110097330A1 (en) 2005-03-11 2011-04-28 Genentech, Inc. Novel Gene Disruptions, Compostitions and Methods Relating Thereto
JP5139271B2 (ja) 2005-05-24 2013-02-06 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 培養した造血幹細胞を拡大しかつ分析する方法
CN101400796B (zh) 2006-03-09 2013-03-27 斯克利普斯研究院 在真细菌宿主细胞内表达正交翻译组分的系统
US8889652B2 (en) 2006-12-06 2014-11-18 Seikagaku Corporation Pharmaceutical agent having long-lasting effect of treating arthritic disorders
KR101503937B1 (ko) 2006-12-08 2015-03-18 렉시컨 파마슈티컬스 인코퍼레이티드 Ａｎｇｐｔｌ３ 에 대한 단일클론 항체
US8575397B2 (en) 2007-02-14 2013-11-05 Biocompatibles Uk Limited Derivatisation of biological molecules
JP2010525836A (ja) 2007-05-04 2010-07-29 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ヒト造血幹細胞のｅｘｖｉｖｏ増殖
CA2826142A1 (en) 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN104619727B (zh) 2012-06-25 2019-04-05 布里格姆及妇女医院股份有限公司 靶向治疗
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215451A1 (en) 2001-11-16 2003-11-20 Napoleone Ferrara Composition comprising and method of using angiopoietin-like protein 3 Angptl3
WO2011008773A2 (en) 2009-07-14 2011-01-20 The Scripps Research Institute Mesenchymal stem cell differentiation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024122720A1 (ko) * 2022-12-09 2024-06-13 (주)케어젠 연골 재생용 펩타이드 및 이의 용도

Also Published As

Publication number Publication date
AU2014225348B2 (en) 2016-03-31
CN105025917B (zh) 2020-08-18
MX365157B (es) 2019-05-24
US9649359B2 (en) 2017-05-16
SG11201506490TA (en) 2015-09-29
AU2016277608A1 (en) 2017-01-12
EP3391900A1 (en) 2018-10-24
CY1120729T1 (el) 2019-12-11
US20160008433A1 (en) 2016-01-14
JO3564B1 (ar) 2020-07-05
AP2015008675A0 (en) 2015-08-31
US20170252407A1 (en) 2017-09-07
TN2015000385A1 (en) 2017-01-03
NZ711037A (en) 2018-07-27
US11179442B2 (en) 2021-11-23
IL240727A0 (en) 2015-10-29
JP2021178841A (ja) 2021-11-18
ZA201505966B (en) 2017-03-29
US20220184182A1 (en) 2022-06-16
CR20150466A (es) 2015-10-27
HUE038499T2 (hu) 2018-10-29
CR20200290A (es) 2020-08-27
BR122016021558A2 (pt) 2019-07-30
EP2964250A1 (en) 2016-01-13
TWI634124B (zh) 2018-09-01
JP6567429B2 (ja) 2019-08-28
UY35368A (es) 2014-10-31
RS57446B1 (sr) 2018-09-28
DK2964250T3 (da) 2018-08-06
AU2016277608B2 (en) 2018-04-05
EP2964250B1 (en) 2018-05-16
CA2903448C (en) 2021-03-23
BR112015021269A2 (pt) 2017-10-10
BR122016021558B1 (pt) 2023-03-28
US20200268849A1 (en) 2020-08-27
AU2016203028B2 (en) 2017-02-02
PL2964250T3 (pl) 2018-10-31
EA035158B1 (ru) 2020-05-06
ES2684349T3 (es) 2018-10-02
PH12015501983B1 (en) 2020-09-25
LT2964250T (lt) 2018-07-25
CN111808182A (zh) 2020-10-23
IL240727B (en) 2019-12-31
PH12015501983A1 (en) 2016-01-11
AU2016203028C1 (en) 2017-06-01
MY173172A (en) 2020-01-02
CN105025917A (zh) 2015-11-04
JP2016510763A (ja) 2016-04-11
CU24301B1 (es) 2017-12-08
AU2014225348A1 (en) 2015-09-10
ECSP15042898A (es) 2019-03-29
KR20150125712A (ko) 2015-11-09
CL2015002443A1 (es) 2016-05-20
PE20151528A1 (es) 2015-11-14
SI2964250T1 (sl) 2018-11-30
US10328126B2 (en) 2019-06-25
CU20150097A7 (es) 2016-05-30
HK1214754A1 (en) 2016-08-05
MX2015011963A (es) 2015-12-09
WO2014138687A1 (en) 2014-09-12
CO7461145A2 (es) 2015-11-30
JP6918871B2 (ja) 2021-08-11
BR112015021269B1 (pt) 2023-04-11
TW201444865A (zh) 2014-12-01
EA201591661A1 (ru) 2015-12-30
PT2964250T (pt) 2018-10-19
AU2016203028A1 (en) 2016-05-26
HRP20181269T1 (hr) 2018-10-19
JP2020015725A (ja) 2020-01-30
CA2903448A1 (en) 2014-09-12

Similar Documents

Publication Publication Date Title
KR102267341B1 (ko) 관절 손상의 치료를 위한 펩티드 및 조성물
US20220402987A1 (en) Peptides and compositions for treatment of joint damage
HK1260928A1 (en) Peptides and compositions for treatment of joint damage
HK40038214A (en) Peptides and compositions for treatment of joint damage
HK1214754B (en) Peptides and compositions for treatment of joint damage

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151005

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190226

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200616

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210325

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210615

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210615

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250529

Start annual number: 5

End annual number: 5